IRIS Accounts Production v23.1.0.753 06881976 Board of Directors 1.5.22 30.4.23 30.4.23 false true false false true false Ordinary 1.00000 Ordinary A 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure068819762022-04-30068819762023-04-30068819762022-05-012023-04-30068819762021-04-30068819762021-05-012022-04-30068819762022-04-3006881976ns16:EnglandWales2022-05-012023-04-3006881976ns15:PoundSterling2022-05-012023-04-3006881976ns11:Director12022-05-012023-04-3006881976ns11:PrivateLimitedCompanyLtd2022-05-012023-04-3006881976ns11:SmallEntities2022-05-012023-04-3006881976ns11:AuditExempt-NoAccountantsReport2022-05-012023-04-3006881976ns11:SmallCompaniesRegimeForDirectorsReport2022-05-012023-04-3006881976ns11:SmallCompaniesRegimeForAccounts2022-05-012023-04-3006881976ns11:AbridgedAccounts2022-05-012023-04-3006881976ns11:OrdinaryShareClass12022-05-012023-04-3006881976ns11:OrdinaryShareClass22022-05-012023-04-3006881976ns11:OrdinaryShareClass32022-05-012023-04-3006881976ns11:Director22022-05-012023-04-3006881976ns11:CompanySecretary12022-05-012023-04-3006881976ns11:RegisteredOffice2022-05-012023-04-3006881976ns6:CurrentFinancialInstruments2023-04-3006881976ns6:CurrentFinancialInstruments2022-04-3006881976ns6:ShareCapital2023-04-3006881976ns6:ShareCapital2022-04-3006881976ns6:RetainedEarningsAccumulatedLosses2023-04-3006881976ns6:RetainedEarningsAccumulatedLosses2022-04-3006881976ns6:FurnitureFittings2022-05-012023-04-3006881976ns6:ComputerEquipment2022-05-012023-04-3006881976ns11:OrdinaryShareClass12023-04-3006881976ns11:OrdinaryShareClass22023-04-3006881976ns11:OrdinaryShareClass32023-04-30
REGISTERED NUMBER: 06881976 (England and Wales)











Abridged Unaudited Financial Statements

for the Year Ended 30th April 2023

for

Pivotal 4Pharma Limited

Pivotal 4Pharma Limited (Registered number: 06881976)






Contents of the Financial Statements
for the Year Ended 30th April 2023




Page

Company Information 1

Abridged Statement of Financial Position 2

Notes to the Financial Statements 3


Pivotal 4Pharma Limited

Company Information
for the Year Ended 30th April 2023







DIRECTORS: T Sheldon
Mrs R Sheldon





SECRETARY:





REGISTERED OFFICE: 5 Armistead Way
Cranage
Holmes Chapel
Cheshire
CW4 8FE





REGISTERED NUMBER: 06881976 (England and Wales)





ACCOUNTANTS: Hammond McNulty LLP
Bank House
Market Square
Congleton
Cheshire
CW12 1ET

Pivotal 4Pharma Limited (Registered number: 06881976)

Abridged Statement of Financial Position
30th April 2023

30/4/23 30/4/22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 - 771

CURRENT ASSETS
Debtors 2,612 -
Cash at bank 4,785 48,820
7,397 48,820
CREDITORS
Amounts falling due within one year 6,596 8,711
NET CURRENT ASSETS 801 40,109
TOTAL ASSETS LESS CURRENT
LIABILITIES

801

40,880

CAPITAL AND RESERVES
Called up share capital 5 4 4
Retained earnings 797 40,876
SHAREHOLDERS' FUNDS 801 40,880

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th April 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Statement of Financial Position for the year ended 30th April 2023 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1st June 2023 and were signed on its behalf by:



T Sheldon - Director


Pivotal 4Pharma Limited (Registered number: 06881976)

Notes to the Financial Statements
for the Year Ended 30th April 2023

1. STATUTORY INFORMATION

Pivotal 4Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The directors have considered the potential impact of COVID-19 on the principal activities of the business and they believe that they have sufficient resources in place to operate for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the financial statements

Turnover
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for services rendered, stated net of discounts and of Value Added Tax.
Income is recognised when services have been delivered to customers

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 15% on reducing balance
Computer equipment - 33% on reducing balance

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Financial instruments
The following assets and liabilities are classified as financial instruments - trade debtors, trade creditors and directors loans.

Directors loans (being repayable on demand), trade debtors and trade creditors are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.
Financial assets that are measured at amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence is found, an impairment loss is recognised in the statement of income and Retained Earnings.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1 ) .

Pivotal 4Pharma Limited (Registered number: 06881976)

Notes to the Financial Statements - continued
for the Year Ended 30th April 2023

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1st May 2022 9,055
Disposals (9,055 )
At 30th April 2023 -
DEPRECIATION
At 1st May 2022 8,284
Eliminated on disposal (8,284 )
At 30th April 2023 -
NET BOOK VALUE
At 30th April 2023 -
At 30th April 2022 771

5. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30/4/23 30/4/22
value: £    £   
2 Ordinary £1 2 2
1 Ordinary A £1 1 1
1 Ordinary B £1 1 1
4 4

6. ULTIMATE CONTROLLING PARTY

Mr T and Mrs R Sheldon, the directors control the company by virtue of holding 100% of the issued ordinary share capital.